[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653547":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":27,"studyPopulation":20,"armGroups":28,"interventions":40,"overallOfficials":48,"centralContacts":56,"locations":64,"responsibleParty":84,"collaborators":20,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":20,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":20,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":20,"overallStatus":107,"whyStopped":20,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"RESnTEC, Institute of Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Treatment efficacy","Increase in the post-treatment North Star Ambulatory Assessment (NSAA) scores will be noted.","6 month after start of treatment",[14,17],{"measure":15,"description":16,"timeFrame":12},"Weight gain","The frequency of patients who will gain weight as an adverse effect, will be noted",{"measure":18,"description":19,"timeFrame":12},"Hyperglycemia","The frequency of patients who will who will develop hyperglycemia as an adverse effect will be noted.",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE","The study will provide evidence to support the standardization of corticosteroid therapy in the local population. By directly comparing alternate-day versus intermittent dosing at The University of Child Health Sciences \\& Children's Hospital, Lahore, the study aims to identify the regimen that best preserves motor function while minimizing debilitating side effects, thereby improving overall quality of life and treatment compliance among local patients with Duchenne Muscular Dystrophy (DMD).",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"Alternate-Day Prednisolone-Group","EXPERIMENTAL","Patients will be given alternate-day administration of prednisolone at a dose of 0.75 mg\u002Fkg\u002Fday.",[34],"Drug: Alternate-day prednisolone",{"label":36,"type":31,"description":37,"interventionNames":38},"Intermittent Prednisolone-Group","Patients will be administered prednisolone at a dose of 0.75 mg\u002Fkg\u002Fday for 10 consecutive days, followed by a 10-day steroid-free period.",[39],"Drug: Intermittent prednisolone",[41,45],{"type":42,"name":43,"description":32,"armGroupLabels":44,"otherNames":20},"DRUG","Alternate-day prednisolone",[30],{"type":42,"name":46,"description":37,"armGroupLabels":47,"otherNames":20},"Intermittent prednisolone",[36],[49,53],{"name":50,"affiliation":51,"role":52},"Nida Imdad","Children's Hospital\u002FUniversity of Child Health Sciences, Lahore","PRINCIPAL_INVESTIGATOR",{"name":54,"affiliation":51,"role":55},"Tipu Sultan, FCPS","STUDY_DIRECTOR",[57,61],{"name":50,"role":58,"phone":59,"phoneExt":20,"email":60},"CONTACT","+923217840636","nidaimdad50@yahoo.com",{"name":54,"role":58,"phone":62,"phoneExt":20,"email":63},"+923334086668","drtipusultan@gmail.com",[65],{"facility":66,"status":20,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Children's Hospital\u002FUniversity of Child Health Sciences","Lahore","Punjab Province","54600","Pakistan","PK",{"type":73,"coordinates":74},"Point",[75,76],74.35071,31.558,{"lat":76,"lon":75},[79,80,81,82],{"name":50,"role":58,"phone":59,"phoneExt":20,"email":60},{"name":54,"role":58,"phone":62,"phoneExt":20,"email":63},{"name":50,"role":52,"phone":20,"phoneExt":20,"email":20},{"name":83,"role":52,"phone":20,"phoneExt":20,"email":20},"Tipu Sultan",{"type":85,"investigatorFullName":86,"investigatorTitle":87,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Muhammad Aamir Latif","Research Consultant","100653547","intermittent-vs-alternate-daily-regimen-of-prednisolone-in-ambulatory-boys-with-duchenne-muscular-dystrophy-100653547",false,"NCT07787689","Intermittent vs Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy","Efficacy and Safety of Intermittent vs. Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy: A Randomized, Open-Label Trial","Inclusion Criteria:\n\n* Male patients\n* Aged 4-10 years\n* 2\\. Confirmed diagnosis of DMD (via genetic testing and significantly elevated creatine kinase (CK) levels \\>1000 U\u002FL with typical clinical presentation)\n\nExclusion Criteria:\n\n* Patients with pre-existing cardiopulmonary failure\n* Patients entirely unable to perform baseline ambulatory assessments (non-ambulatory)\n* Patients with clinically suspected muscular dystrophy with normal genetic study for DMD","MALE","4 Years","10 Years",{"count":99,"type":100},40,"ESTIMATED","INTERVENTIONAL",[103],"NA","The alternate-day regimen is hypothesized to reduce hypothalamic-pituitary-adrenal (HPA) axis suppression and decrease steroid-related toxicity. Similarly, intermittent regimens aim to provide periodic steroid exposure sufficient for muscle preservation while allowing recovery periods to limit side effects. There is a critical need for localized, prospective data to determine which protocol offers the optimal balance of efficacy and safety for pediatric patients in Pakistan.",[106],"Duchenne Muscular Dystrophy","NOT_YET_RECRUITING","2026-08-22",{"date":110,"type":111},"2026-08-26","ACTUAL",{"date":113,"type":100},"2026-09-15",{"date":115,"type":100},"2027-03-15",{"name":86,"class":6},1]